Results

1–10 of 179 results for Age-Related Macular Degeneration

Novel Handheld Device for Remote Monitoring of Non-neovascular Age-Related Macular Degeneration andClinical Validation of Usability and Comfort
Yannis M Paulus, MD
Annual Meeting Talks
2025
LIGHTSITE IIIB: A Prospective, Multi-Center Extension Study to Assess the Long-Term Safety and Efficacy ofPhotobiomodulation in Dry Age-Related Macular Degeneration
David S. Boyer, MD
Annual Meeting Talks
2025
Evaluating the Visual, Anatomic, and Treatment Effects of Switching from Higher-cost Anti-VEGF to Lower-cost Bevacizumab After Loss of Copay Assistance (Good Days) Funding in Neovascular Age-Related Macular Degeneration
Jesse J Jung, MD, FASRS
Updates from the Field
2026
CD 46 is a Potent Complement Cofactor as Part of a Clinical Strategy for Geographic Atrophy
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2026
OTX-TKI for the Treatment of Neovascular Age-related Macular Degeneration 12-Month Results From a US Clinical Trial
Robert L. Avery, MD
Annual Meeting Talks
2023
Intended vs Actual Intervals Between Intravitreal Anti-VEGF Injections and Assessment of Treatment Delays
Christina Y Weng, MD, MBA, FASRS
Annual Meeting Talks
2023
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Annual Meeting Talks
2023
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Annual Meeting Talks
2023
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2023